Regenxbio settles Sarepta patent litigation over Elevidys for USD 39 million

• Regenxbio settled patent infringement litigation over Sarepta’s SRP-9001, marketed in the US as Elevidys, tied to two AAVrh74 capsid patents.
• Sarepta will pay USD 39 million within 10 days of the settlement’s effective date.
• The parties will dismiss the patent cases with prejudice, ending ongoing litigation over the patents-in-suit.
• The agreement includes releases and a covenant not to sue covering AAVrh74-based Sarepta gene therapies, including Elevidys.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-399377), on September 23, 2026, and is solely responsible for the information contained therein.